Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder
Abstract
We systematically analyzed postzygotic mutations (PZMs) in whole-exome sequences from the largest collection of trios (5,947) with autism spectrum disorder (ASD) available, including 282 unpublished trios, and performed resequencing using multiple independent technologies. We identified 7.5% of de novo mutations as PZMs, 83.3% of which were not described in previous studies. Damaging, nonsynonymous PZMs within critical exons of prenatally expressed genes were more common in ASD probands than controls (P < 1 × 10-6), and genes carrying these PZMs were enriched for expression in the amygdala (P = 5.4 × 10-3). Two genes (KLF16 and MSANTD2) were significantly enriched for PZMs genome-wide, and other PZMs involved genes (SCN2A, HNRNPU and SMARCA4) whose mutation is known to cause ASD or other neurodevelopmental disorders. PZMs constitute a significant proportion of de novo mutations and contribute importantly to ASD risk.
Domains
Human genetics
Fichier principal
nihms881982.pdf (654.59 Ko)
Télécharger le fichier
NIHMS881982-supplement-1.pdf (157.85 Ko)
Télécharger le fichier
NIHMS881982-supplement-2.pdf (272.01 Ko)
Télécharger le fichier
NIHMS881982-supplement-3.pdf (130.85 Ko)
Télécharger le fichier
Origin : Publisher files allowed on an open archive